Resources
BeiGene Medical Europe

Tislelizumab for relapsed/refractory peripheral T-cell lymphomas

 Back View
Tislelizumab for relapsed/refractory peripheral T-cell lymphomas
 ABSTRACT   06/2020
 View

For more information about this resource, please submit a medical information request.

Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: safety and efficacy results from a phase 2 study

Rating

Rate this resource

Related resources

Tislelizumab - Mode of Action
Tislelizumab - Mode of Action
PD-1 inhibitors for NSCLC: Where are we now?
PD-1 inhibitors for NSCLC: Where are we now?
PD-1 inhibitors on the horizon for NSCLC: Symposium closing address
PD-1 inhibitors on the horizon for NSCLC: Symposium closing address
 Back

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service